Vitamin D pathway gene variants and HCV-2/3 therapy outcomes

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 335-341

  Cusato, Jessica ^a   Allegra, Sarah ^a   Boglione, Lucio ^a   De Nicolò, Amedeo ^a   Baietto, Lorena ^a   Cariti, Giuseppe ^a   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; VITAMIN D; ANTIVIRUS AGENT; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; COLECALCIFEROL 24 HYDROXYLASE; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CYP24A1 GENE; CYP27B1 GENE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VDR GENE; GENE LINKAGE DISEQUILIBRIUM; GENETICS; GENOTYPE; HEPACIVIRUS; METABOLISM; MIDDLE AGED; PHARMACOGENETICS; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS LOAD;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADULT; ANTIVIRAL AGENTS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRAL LOAD; VITAMIN D; VITAMIN D3 24-HYDROXYLASE;

EID: 84936160263     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2853     Document Type: Article

References (15)

1. Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014; 142:270-286.
2. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol 2013; 29:243-249.
3. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
4. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
5. Thimme R, Bukh J, Spangenberg HC, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002; 99:15661-15668.
6. Poon AH, Gong L, Brasch-Andersen C, et al. Very important pharmacogene summary for VDR. Pharmacogenet Genomics 2012; 22:758-763.
7. Stokes CS, Volmer DA, Grunhage F, Lammert F. Vitamin D in chronic liver disease. Liver Int 2013; 33:338-352.
8. Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011; 9:688-693.
9. Huang CF, Dai CY, Yeh ML, et al. Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS ONE 2013; 8:e58882.
10. Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS ONE 2012; 7:e45698.
11. Sarin SK, Kumar CK. Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies. Liver Int 2012; 32 Suppl 1:141-145.
12. Mangia A, Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol 2013; 19:8924-8928.
13. García-Martín E, Agundez JA, Maestro ML, et al. Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS ONE 2013; 8:e74764.
14. D'Avolio A, Ciancio A, Siccardi M, et al. Negative predictive value of IL28B, SLC28A2 and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFNRBV treatment. Ther Drug Monit 2012; 34:722-728.
15. Holt SK, Kwon EM, Koopmeiners JS, et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 2010; 70:1448-1460.